Last reviewed · How we verify
ASCT conditioning — Competitive Intelligence Brief
phase 3
High-dose chemotherapy conditioning regimen
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
ASCT conditioning (ASCT conditioning) — Prof. Dr. M. Dreyling (co-chairman). ASCT conditioning is a high-dose chemotherapy regimen used to prepare the bone marrow for autologous stem cell transplantation by eliminating malignant cells and creating space for donor stem cells to engraft.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ASCT conditioning TARGET | ASCT conditioning | Prof. Dr. M. Dreyling (co-chairman) | phase 3 | High-dose chemotherapy conditioning regimen |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (High-dose chemotherapy conditioning regimen class)
- Prof. Dr. M. Dreyling (co-chairman) · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ASCT conditioning CI watch — RSS
- ASCT conditioning CI watch — Atom
- ASCT conditioning CI watch — JSON
- ASCT conditioning alone — RSS
- Whole High-dose chemotherapy conditioning regimen class — RSS
Cite this brief
Drug Landscape (2026). ASCT conditioning — Competitive Intelligence Brief. https://druglandscape.com/ci/asct-conditioning. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab